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Abstract
Recently, we and others reported a recurrent t(7;12)(q36;p13) found in
myeloid malignancies in children <18 months of age and associated with
a poor prognosis. Fluorescence in situ hybridization studies mapped the
12p13 breakpoint to the first intron of ETV6 and narrowed down the
region of 7q36 involved. By using the sequences made public recently by
the Human Genome Project, two candidate genes in 7q36 were identified:
the homeobox gene HLXB9 and c7orf3, a gene with unknown function.
Reverse transcription-PCR of two cases with t(7;12), using primers for
c7orf3 and ETV6, was negative. However, reverse transcription-PCR for
HLXB9-ETV6 demonstrated alternative splicing; the two major bands
corresponded to fusion of exon 1 of HLXB9 to exons 2 and 3, respectively,
of ETV6. The reciprocal ETV6-HLXB9 transcript was not detected. It
remains to be elucidated if the leukemic phenotype is attributable to the
formation of the HLXB9-ETV6 fusion protein, which includes the helix-
loop-helix and E26 transformation-specific DNA binding domains of
ETV6 or to the disruption of the normal ETV6 protein.
Introduction
ETV6 (TEL), a member of the ETS4 family of transcription factors,
located on 12p13, is known to be rearranged in a spectrum of hema-
tological malignancies. These rearrangements often take the form of
translocations, some of which can only be identified using molecular
(cytogenetic) techniques5 (1). To date, .10 different fusion partners
to ETV6 have been identified in acute lymphoblastic leukemia, AML,
and myelodysplastic syndromes.5 The characterization of these chi-
meras has shown that different regions of ETV6 are involved in these
translocations. Fusion of the HLH-domain of ETV6 to the 39 region of
the partner can influence and stimulate the activity of the partner gene,
as seen in t(5;12)(q33;p13), t(9;12)(q34;p13), t(9;12)(p24;p13), and
t(12;21)(p13;q22), involving PDGFRB, ABL1, JAK2, and AML1, re-
spectively (2). ETV6 can drive the transcription of the partner gene as
occurs in t(3;12)(q26;p13) with MDS1/EVI1 or in t(12;13)(p13;q12)
with the homeobox gene CDX2 (3). A third type of fusion is where the
partner gene forms a chimera with the 39 part of ETV6, retaining the
ETV6 HLH and ETS DNA binding domains, as shown for MN1 in
t(12;22)(p13;q11) and BTL in t(4;12)(q11;p13) (4, 5). We, and others,
recently described a novel recurrent translocation, (7;12)(q36;p13),
occurring in children #18 months of age with mainly myeloid disor-
ders (6, 7). This translocation was found in ;20% of Dutch patients
with AML in this age group, making it the most common aberration
next to translocations involving MLL (7). Survival data suggest that
the presence of the t(7;12)(q36;p13), similar to MLL rearrangements,
confers a poor prognosis (7). FISH studies revealed the involvement
of ETV6 and helped to narrow down the relevant region of 7q36.
Using material available from two of our patients, we have been able
to show that HLXB9 is the partner gene of ETV6 in this translocation.
Materials and Methods
Case Reports, Cytogenetics, and FISH. The clinical, cytogenetic, and
FISH features of both patients have been reported previously (7). In short, case
1 (patient 2 in Ref. 7) was a 4-month-old boy with AML M1, who died 3
months after diagnosis. The karyotype, refined by FISH, was 47,XY,der(7)t(7;
12)(q36;p13)del (12)(p13p13),der (12)t(7;12),119. Case 2 (patient 3 in Ref. 7)
was an 18-month-old boy with AML M3 variant, without PML/RARA fusion,
who died 39 months after diagnosis. The karyotype, refined by FISH, was
47,XY,t(7;12)(q36;p13),119. No MLL rearrangements were observed in either
case. The FISH studies were carried out using a range of cosmid probes for
ETV6 (1). In both patients, the translocation was shown to have a breakpoint
in intron 1 of ETV6, and in case 1, this was accompanied by a deletion of ETV6
distal to this. Significantly, in case 2, we found that the CEPH YAC 965c12
(locus D7S550; size 160 kb), localized to 7q36, did span the breakpoint.
Nucleic Acid Isolation. Total RNA from both cases was extracted from
cryopreserved bone marrow cells, stored in liquid nitrogen at the time of
diagnosis, using the RNeasy kit (Qiagen, Hilden, Germany). Total RNA
extracted from the NB4 cell line known to have t(15;17)(q22;q12), using the
Trizol reagent (Life Technologies, Inc., Stockholm, Sweden), was used as
negative control RNA.
5* RACE. The 59 RACE was performed on 1 mg of total RNA from both
cases using the SMART RACE cDNA amplification kit (CLONTECH, Palo
Alto, CA) with oligo TELR1 (Table 1). Obtained clones were screened by
Southern blotting with end-labeled oligo TELR2, located in exon 2 to ensure
the inclusion of upstream ETV6 sequences, and with TELF1 located in exon 1
to rule out ETV6-containing gene products.
RT-PCR Analysis. One, 2.5, and 5 mg of total RNA from cases 1, 2, and
the cell line NB4, respectively, were reverse transcribed and PCR amplified as
described previously (8). The primers used for PCR amplification are listed in
Table 1. The HXLB9-ETV6 fusion transcript was detected using HLX9-545F
and TEL172R and reamplified with HLXB9-604F and TEL143R, HLXB9-
604F, and TEL163R or HLXB9-604F and TEL135R. For amplification of a
possible C7orf3-ETV6 fusion transcript, cDNA was amplified with C7orf3-
608F and TEL172R and reamplified with C7orf3-712F and TEL143R. For the
detection of the reciprocal ETV6-HLXB9 fusion transcript, ETV6F1a and
HLXB9-1092R and ETV6F1b and HLXB9-989R were used as primer com-
binations.
Sequence Analysis. PCR-amplified fragments were directly sequenced
using the dideoxy procedure with an ABI Prism BigDye terminator cycle
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sequencing ready reaction kit (PE Applied Biosystems, Foster City, CA) with
various primers (Table 1).
Results and Discussion
We have demonstrated previously that in the present cases with the
t(7;12)(q36;p13), the breakpoint in ETV6 was located in intron 1.
Furthermore, in case 1, a concomitant deletion of 59 sequences com-
prising at least part of intron 1, exon 1, and part of the upstream
sequences of exon 1 was found (7). The latter finding strongly
suggested that the fusion product encoded by the der(12)t(7;12), being
59 partner-39 ETV6, would be the pathogenically important chimera.
Consequently, we initially used 59 RACE to attempt to identify the
translocation partner, but only sequences corresponding to upstream
ETV6 exons and introns were retrieved.
Our FISH experiments on case 2 using CEPH YAC 965c12 showed
signals on both the der(7) and the der(12) (7). Although this YAC is
reported to have a size of 160 kb, it most probably has a large deletion
because it contains the markers D7S550, CHL.ATC3E04, D7S2307,
and D7S2380,6 the first three of which are all localized to NT_007905
(National Center for Biotechnology Information, GenBank) in the
vicinity of the SHH gene, and the last is located on NT_007951, which
is at least 1 Mb more telomeric on 7q36. Tosi et al. (6) described three
cases with t(7;12)(q36;p13) that had the breakpoint on 7q36 within
PAC H_DJ1121A15. They also showed in these cases that two cos-
mids, derived from this PAC, were translocated to the der(12), indi-
cating that the breakpoint should be proximal to the cosmids used.
This PAC of 130 kb has been sequenced (GenBank accession no.
AC006357) and is known to contain the homeobox gene HLXB9.
In another of Tosi’s patients, also with a t(7;12)(q36;p13), a break-
point distal to both the PAC and one of the cosmids was observed (6),
suggesting breakpoint heterogeneity.
The genomic and transcriptional region around HLXB9 has been
well characterized by Heus et al. (9) in their search for the gene defect
causing preaxial polydactyly, mapped to a 1.9-cM region on 7q36
between D7S550 and D7S2423. In this candidate region, centromeric
to HLXB9, they identified three transcripts called C7orf3, C7orf2, and
C7orf4, with C7orf3 immediately adjacent to HLXB9. This, together
with the results obtained by Tosi et al. (6), made C7orf3 a possible
candidate for fusion to ETV6. Alignment of the HLXB9 and c7orf3
cDNAs to the PAC revealed that the genes have opposite orientations:
c7orf3 is transcribed from centromere to telomere, whereas HLXB9,
as well as ETV6, are transcribed from telomere to centromere. Thus,
the orientation of ETV6 is opposite to that of c7orf3, indicating that an
in-frame fusion of these two genes cannot occur after a simple
translocation but requires a more complex mechanism comparable
with that which is presumed to occur in ETV6-ABL1 fusions (10). The
orientation, however, of the HLXB9 gene does match the criteria for
an in-frame fusion with ETV6 by means of a simple translocation.
RT-PCR with two C7orf3 forward and two ETV6 reverse primer
combinations did not amplify any cDNA product from the patients’
samples (Fig. 1, Lanes 4 and 5), strongly suggesting that a C7orf3-
ETV6 chimeric transcript was not present. However, RT-PCR using
two HLXB9 forward and various ETV6 reverse primers on cDNA
from both cases did amplify cDNA fragments, suggesting the pres-
ence of an HLXB-9-ETV6 chimeric gene (Fig. 1, Lanes 1 and 2). The
HLXB9-604F and TEL143R primer combination amplified multiple
cDNA fragments, with two major bands: one of 356 bp and the other
of 486 bp (the 486-bp fragment was weakly amplified in case 1; Fig.
1, Lane 1). The HLXB9-604F and TEL135R primer combination
amplified two cDNA fragments of 329 and 459 bp, whereas the
primers HLXB9-604F and TEL163R amplified two fragments of 416
and 546 bp (data not shown). Nested PCR with two forward primers
located in exon 1 of the ETV6 gene and two reverse primers located
in exon 3 of the HLXB9 gene did not amplify any cDNA product,
suggesting that the reciprocal ETV6-HLXB9 was not expressed (data
not shown).
To verify the presence of HLXB9-ETV6 chimeric transcripts, the
356- and 486-bp cDNA fragments were sequenced. This analysis
revealed two types of chimeric HLXB9-ETV6 transcripts. In the
356-bp transcript, nt 694 of HLXB9 (NM_005515), corresponding to
the end of exon 1, was fused to nt 188 of ETV6 (NM_001987),
corresponding to exon 3, resulting in an in-frame junction with a
serine-to-cysteine (TCC to TGC) transition (Fig. 2). In the 486-bp
6 Internet address: http://www.genet.sickkids.on.ca/chromosome7.
Table 1 Primers used for PCR and sequencing
Designation Sequence (59 3 39) Direction Position Gene (accession no.)
TELR1 CCTGCTCCAGTAAATTGGCTGCAAGCG Reverse 187–213 ETV6 (NM_001987)
TELR2 GGCAGGCGGATCGAGTCTTCCTCC Reverse 153–176 ETV6 (NM_001987)
TELF1 GATCTCTCTCGCTGTGAGACATG Forward 5–27 ETV6 (NM_001987)
TEL301R CTCTTTGGTCAGCAGCAGGAGAGC Reverse 301–324 ETV6 (NM_001987)
TEL135R GTGGAAGAATGGTGAAAGAATCCGAGG Reverse 400–429 ETV6 (NM_001987)
TEL143R CTGTGAGTGTATAGAGTTTCCAGGGTG Reverse 427–453 ETV6 (NM_001987)
TEL163R CCTGGGCCTCCTCTGGACACAGTTATC Reverse 487–513 ETV6 (NM_001987)
TEL172R GTTATGGTGCACATTATCCACGGATGG Reverse 514–540 ETV6 (NM_001987)
ETV6F1a TGAGACATGTCTGAGACTCCTGCT Forward 19–42 ETV6 (NM_001987)
ETV6F1b ACTCCTGCTCAGTGTAGCATTAAG Forward 34–57 ETV6 (NM_001987)
HLXB9-545F CGCTCTCCTACTCGTACCCGCAG Forward 545–567 HLXB9 (NM_005515)
HLXB9-604F ATCAAGCTGGGCGCCGGCACCT Forward 604–625 HLXB9 (NM_005515)
HLXB9-624F CTTCCAGCTGGACCAGTGGCTG Forward 624–645 HLXB9 (NM_005515)
HLXB9-989R GGCCCCAGCAGCTCCTCGGCTC Reverse 989–1010 HLXB9 (NM_005515)
HLXB9-1092R TGCTGTAGGGGAAATGGTCCTCG Reverse 1092–1114 HLXB9 (NM_005515)
C7orf3-608F TCAGTGGGCAGCTGGAGGAACTG Forward 609–631 C7orf3 (AF107455)
C7orf3-712F GCCCAGCAGACTGATGATGGAGC Forward 712–734 C7orf3 (AF107455)
Fig. 1. RT-PCR for the detection of HLXB9-ETV6 and c7orf3-ETV6 transcripts in cases
1 and 2 and the NB4 control cell line. Nested PCR results are shown in Lanes 1–3 using
primers HLXB9-604F and ETV6143R: Lane 1, case 1; Lane 2, case 2; Lane 3, NB4.
Nested PCR results using primers C7orf3-712F and TEL143R are shown in Lanes 4–6:
Lane 4, case 1; Lane 5, case 2; Lane 6, NB4.
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transcript, nt 694 of HLXB9 was fused out of frame to nt 58, corre-
sponding to exon 2, of ETV6 (Fig. 2), confirming that the observed
cDNA fragments are indeed alternatively spliced products.
HLXB9, also known as HB9, is a homeobox gene of, presumably,
three exons resulting in an open reading frame of 1,206-bp coding for
a protein of 403 amino acids (11). The gene has a high GC content
(75%), which might explain the problems encountered in the at-
tempted 59RACE PCR. Transcripts of 2.2 kb are expressed in the
colon, small intestine, and pancreas. In addition, HLXB9 is highly
expressed in CD341 bone marrow cells as transcripts of 5.3 and 3.9
kb; this expression is not observed in CD342 cells. In the CD341
cells, HLXB9 expression increases upon exposure to interleukin 3 and
granulocyte macrophage colony-stimulating factor, followed by
down-regulation upon differentiation, showing it to be a marker of
immature hematopoietic cells (12). The gene could therefore be in-
volved in the regulation of growth and differentiation of progenitor
cells. Elevated HLXB9 expression has also been observed in acute
lymphoblastic leukemia or AML, but not in chronic lymphocytic
leukemia or chronic myeloid leukemia patients, or in acute leukemias
in complete remission (13). In addition, a mutation in HLXB9 is the
cause of dominantly inherited sacral agenesis (14), which together
with anorectal malformation, a presacral mass, and urogenital mal-
formation is referred to as the Currarino syndrome.
In the two patients described here, the t(7;12)(q36;p13) results in
fusion of the NH2 terminus of HLXB9 to the COOH terminus of
ETV6 (Fig. 3). The fusion transcript creates a chimeric protein that
contains the ETV6 HLH and the ETS domains, which are joined to the
regulatory sequences and the first exon of HLXB9, but no longer
contains the HLXB9 homeobox domain. The type of fusion protein
formed is similar to the MN1-ETV6 and the BTL-ETV6 chimeras (4,
5). In the t(7;12)(q36;p13), the HLXB9-ETV6 fusion protein is under
the influence of the HLXB9 promoter, which under normal conditions
is down-regulated during differentiation. However, in the leukemia
described here, the down-regulation is disturbed because the cells do
not differentiate. It remains to be elucidated if this differentiation
block might be caused by the formation of the HLXB9-ETV6 fusion
protein or by the disruption of the normal ETV6 protein equilibrium.
The fact that we could only detect the presence of the HLXB9-
ETV6 transcript and not the reciprocal transcript suggests that the
fusion protein driven from the HLXB9 promoter is the leukemogenic
factor. However, additional t(7;12)(q36;p13) cases should be investi-
gated to confirm that HLXB9 is involved in all these translocations.
The young age of the patients identified with the t(7;12)(q36;p13)
suggests that this leukemia may originate in utero as has been dem-
onstrated for leukemias associated with MLL rearrangements (15) and
the t(12;21)(p13;q22), also involving ETV6 (16). This could provide
clues to which etiological factors may play a role in the development
of this type of leukemia.
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